<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1102256876
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Elrexfio
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Elranatamab
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        44
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        9907.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMACIA UPJOHN" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMACIA UPJOHN
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ELREXFIO is a cancer medicine that contains the active substance &lsquo;elranatamab&rsquo;. It is a prescription medicine used to treat adults with multiple myeloma who:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody to treat their multiple myeloma, and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; their cancer has come back or did not respond to prior treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Warnings and precautions </strong></p><p>Tell your doctor or nurse about all of your medical conditions before you are given ELREXFIO, including if you have had any recent infections.</p><p>&nbsp;</p><p><strong>Tests and checks</strong></p><p><strong>Before you are given ELREXFIO</strong>, your doctor will check your blood counts for signs of infection. If you have any infection, it will be treated before you start ELREXFIO. Your doctor will also check if you are pregnant or breast-feeding.</p><p>&nbsp;</p><p><strong>During treatment with ELREXFIO</strong>, your doctor will monitor you for signs and symptoms of serious side effects before you start and during treatment with ELREXFIO and may temporarily or completely stop treatment with ELREXFIO if you develop certain side effects. Your doctor will regularly check your blood counts, as severe abnormal lab test results with ELREXFIO include decreased white blood cells, red blood cells, and platelets.</p><p>&nbsp;</p><p><strong>Look out for serious side effects.</strong></p><p><strong>Tell your doctor or nurse right away if you experience any of the following:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cytokine Release Syndrome (CRS), see section 4 for more information about signs and symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neurologic problems, see section 4 for more information about signs and symptoms.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Your doctor will monitor you for signs and symptoms of CRS and neurologic problems during treatment with ELREXFIO, as well as other side effects, and will treat you if needed. Your doctor may temporarily stop or completely stop your treatment with ELREXFIO if you develop CRS, neurologic problems, or any other side effects that are severe.</p><p>If you have any questions about ELREXFIO, ask your doctor or nurse.</p><p>&nbsp;</p><p><strong>Children </strong></p><p>It is not known if ELREXFIO is safe and effective in children.</p><p>&nbsp;</p><p><strong>Other medicines and ELREXFIO</strong></p><p>Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. This includes prescription and over the counter medicines, vitamins, and herbal supplements.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>ELREXFIO may harm your unborn baby.</p><p>&nbsp;</p><p><u>Pregnancy-information for women</u></p><p>Tell your doctor or nurse before you are given ELREXFIO if you are pregnant, think you might be pregnant or are planning to have a baby.</p><p>&nbsp;</p><p>If you are able to become pregnant, your doctor should do a pregnancy test before you start treatment.</p><p>&nbsp;</p><p>If you become pregnant while being treated with this medicine, tell your doctor or nurse straight away.</p><p>&nbsp;</p><p><u>Contraception</u></p><p>If you could become pregnant, you must use effective birth control (contraception) during treatment and for 4 months after your last dose of ELREXFIO.</p><p><strong>&nbsp;</strong></p><p><u>Breast-feeding</u></p><p>If you are breastfeeding or plan to breastfeed. It is not known if ELREXFIO passes into your breast milk. Do not breastfeed during treatment and for 4 months after your last dose of ELREXFIO.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p><strong>Do not</strong> drive, operate heavy or potentially dangerous machinery, or do other dangerous activities during treatment with ELREXFIO:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for 48 hours after completing each of the 2 doses of ELREXFIO that are part of the &ldquo;step-up dosing schedule&rdquo; and your first full treatment dose, and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at any time during treatment with ELREXFIO if you develop any new neurologic symptoms such as dizziness, confusion, shaking (tremors), sleepiness, or any other symptom that impairs consciousness, until the symptoms go away, see section 4 for more information about signs and symptoms of neurologic problems.</p><p><strong>&nbsp;</strong></p><p><strong>ELREXFIO contains sodium</strong></p><p>ELREXFIO contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free.&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much is given</strong></p><p>Due to the risk of CRS, you will receive ELREXFIO on a &ldquo;step-up dosing schedule&rdquo; and should be hospitalized for 48 hours after the first &ldquo;step-up&rdquo; dose and for 24 hours after the second &ldquo;step-up&rdquo; dose of ELREXFIO.</p><p>&nbsp;</p><p>During the step-up dosing schedule:</p><ul><li>You will receive a &lsquo;step-up dose 1&rsquo; of 12&nbsp;mg on Day 1 of your treatment.</li><li>You will then receive &lsquo;step-up dose 2&rsquo; of 32&nbsp;mg on Day 4 of your treatment.</li><li>You will then receive a &lsquo;full treatment dose&rsquo; of 76&nbsp;mg on Day 8 of your treatment.</li><li>After you receive your first full &ldquo;treatment&rdquo; dose, ELREXFIO is usually given 1 time each week through Week 24, as long as you are getting benefit from ELREXFIO.</li><li>Starting on Week 25, your future doses will usually be given 1 time every 2 weeks, as long as you are getting benefit from ELREXFIO.</li></ul><p>&nbsp;</p><p>If your dose of ELREXFIO is delayed for any reason, you may need to repeat the step-up dosing schedule.</p><p>&nbsp;</p><p>Before each dose of ELREXFIO you receive during the step-up dosing schedule, you will receive medicines to help reduce your risk of CRS. Your doctor will decide if you need to receive medicines to help reduce your risk of CRS with future doses.</p><p>&nbsp;</p><p><strong>How the medicine is given</strong></p><p>ELREXFIO will be given to you by your doctor or nurse as an injection under your skin (subcutaneous injection), usually in your stomach-area (abdomen). Your thigh or another area of your body may also be used.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines given during treatment with ELREXFIO</strong></p><p>You will be given medicines 1 hour before each of your first three doses of ELREXFIO, which help to lower the chance of side effects, such as cytokine release syndrome. These may include:</p><ul><li>Medicine to reduce the risk of fever (such as paracetamol)</li><li>Medicine to reduce the risk of inflammation (corticosteroids)</li><li>Medicine to reduce the risk of an allergic reaction (antihistamines such as diphenhydramine)</li></ul><p>&nbsp;</p><p>You may also be given these medicines for later doses of ELREXFIO based on any symptoms you have.</p><p>&nbsp;</p><p>You may also be given additional medicines based on any symptoms you experience or your medical history.</p><p><strong>&nbsp;</strong></p><p><strong>If you are given more ELREXFIO than you should</strong></p><p>This medicine will be given by your doctor or nurse. In the unlikely event that you are given too much (an overdose) your doctor will check you for side effects.</p><p>&nbsp;</p><p><strong>If you miss your appointment to have ELREXFIO</strong></p><p>If you miss any appointments, call your doctor or nurse as soon as possible to reschedule your appointment. It is important for you to be monitored closely for side effects during treatment with ELREXFIO.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>Get medical help straight away if you get any of the following serious side effects, which may be severe and can be fatal.</p><p>&nbsp;</p><ul><li><strong>Cytokine Release Syndrome (CRS).</strong> CRS is common during treatment with ELREXFIO and can also be serious, life-threatening, or can lead to death. Tell your doctor or nurse or get medical help right away if you develop any signs or symptoms of CRS, including:</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever of 38 &deg;C or higher</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness or light-headedness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heartbeat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased liver enzymes in your blood.</p><p>&nbsp;</p><ul><li><strong>Neurologic problems. </strong>ELREXFIO can cause neurologic problems that can be serious or life-threatening. Tell your doctor or nurse or get medical help right away if you develop any<strong> </strong>signs or symptoms of neurologic problems, including:</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation, trouble staying awake, confusion or disorientation, seeing or hearing things that are not real (hallucinations)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble speaking, thinking, remembering things, paying attention, or understanding things</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems walking, muscle weakness, shaking (tremors), loss of balance, or muscle spasms</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness and tingling (feeling like &ldquo;pins and needles&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burning, throbbing, or stabbing pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in your handwriting</p><p>&nbsp;</p><ul><li><strong>Infections</strong><strong>. </strong>Upper respiratory tract infections and pneumonia are common during treatment with ELREXFIO. ELREXFIO can cause bacterial and viral infections that are severe, life-threatening, or that may lead to death.</li></ul><p>Your doctor may prescribe medicines for you to help prevent infections and treat you as needed if you develop an infection during treatment with ELREXFIO.</p><p>Tell your doctor or nurse right away if you develop any signs or symptoms of an infection during treatment with ELREXFIO, including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever of 38 &deg;C or higher</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain during urination</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak or generally unwell</p><p>&nbsp;</p><ul><li><strong>Decreased</strong><strong> white blood cell counts. </strong>Decreased white blood cell counts are common during treatment with ELREXFIO and can also be severe. Fever can happen with low white blood cell counts and may be a sign that you have an infection. Your doctor will treat you as needed.</li></ul><p><strong>&nbsp;</strong></p><ul><li><strong>Liver problems.</strong><strong> </strong>ELREXFIO can cause increased liver enzymes and bilirubin in your blood. These increases can happen with or without you also having CRS.<strong> </strong>Tell your doctor or nurse if you develop any of the following signs or symptoms of liver problems:</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your right upper stomach-area (abdomen)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of your skin or the white part of your eyes</p><p>&nbsp;</p><p><strong>Very common</strong> <strong>(may affect more than 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A serious immune reaction called &lsquo;cytokine release syndrome&rsquo;</p><ul><li>Low levels of a type of white blood cell (neutropenia)</li><li>Low levels of antibodies called &lsquo;immunoglobulins&rsquo; in the blood (hypogammaglobulinaemia), which may make infections more likely</li><li>Infection</li></ul><p>&nbsp;</p><p><strong>Common</strong> <strong>(may affect up to 1 in 10 people):</strong></p><ul><li>A serious immune reaction called &lsquo;immune effector cell-associated neurotoxicity syndrome&rsquo; (ICANS) that may cause effects on your nervous system.</li></ul><p>&nbsp;</p><p>Tell your doctor right away if you notice any of the above-listed serious side effects.</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Other side effects are listed below. Tell your doctor or nurse if you get any of these side effects.</p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong> <strong>(may affect more than 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low levels of red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection in the nose, sinuses, or throat (upper respiratory tract infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions at or near the injection site, including redness of the skin, itching, swelling, pain, bruising, rash, or bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung infection (pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low levels of blood platelets (cells that help blood to clot; thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low levels of a type of white blood cells (lymphopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry skin or skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in muscles and bones</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of &lsquo;potassium&rsquo; in the blood (hypokalaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being short of breath (dyspnoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe infection throughout the body (sepsis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low number of white blood cells (leucopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased level of liver enzymes in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nerve damage that may cause tingling, numbness, pain, or loss of pain sensation (peripheral neuropathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bladder infection (urinary tract infection)</p><p><strong>&nbsp;</strong></p><p><strong>Common</strong> <strong>(may affect up to 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of &lsquo;phosphate&rsquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low number of a type of white blood cell with a fever (febrile neutropenia)</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ELREXFIO will be stored at the hospital or clinic by your doctor.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Shelf-life: 24 months.</p><p>Do not use this medicine after the expiry date which is stated on the carton and the vial label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&nbsp;&deg;C to 8&nbsp;&deg;C). Do not freeze or shake the vial or carton.</p><p>&nbsp;</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice discolouration or other visible signs of deterioration.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Your doctor or nurse will throw away any medicines that are no longer being used. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is elranatamab. ELREXFIO comes in two different package sizes:</p><p>o&nbsp;&nbsp; One 1.1&nbsp;mL vial contains 44&nbsp;mg of elranatamab (40&nbsp;mg/mL).</p><p>o&nbsp;&nbsp; One 1.9&nbsp;mL vial contains 76&nbsp;mg of elranatamab (40&nbsp;mg/mL).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are Edetate disodium dihydrate, Histidine, L-histidine hydrochloride monohydrate, Polysorbate 80, Sucrose, Water for Injection (see &ldquo;ELREXFIO contains sodium&rdquo; in section 2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	ELREXFIO is a solution for injection (injection) and is a colourless to pale brown liquid.
	ELREXFIO is supplied as a carton pack containing 1 glass vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer Inc.,</p><p>66 Hudson Boulevard East,</p><p>New York, NY 10001,</p><p>United States</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Pharmacia &amp; Upjohn Company<br />7000 Portage Road Kalamazoo, Michigan (MI) 49001, USA<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">الريكسيفيو هو دواء للسرطان يحتوي على المادة الفعالة &quot;إلراناتاماب&quot;. وهو دواء يُصرف بوصفة طبية يُستخدم لعلاج البالغين المصابين بالورم النقوي المتعدد الذين:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلقوا بالفعل ما لا يقل عن ٤ أنظمة علاجية، بما في ذلك مثبط للبروتيازوم، وأحد عوامل تعديل المناعة، وجسم مضاد أحادي النسيلة مستهدف للبروتين CD38، لعلاج الورم النقوي المتعدد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ولكن عاد السرطان لديهم مرة أخرى أو لم يستجب للعلاج السابق.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الاحتياطات عند استعمال الريكسيفيو</strong></p><p dir="RTL">أبلغ طبيبك أو الممرضة بكل ما تعانيه من حالات طبية قبل أن تتلقى الريكسيفيو، بما في ذلك الإصابة بأي حالات عدوى مؤخرًا.</p><p>&nbsp;</p><p dir="RTL"><strong>الاختبارات والفحوصات</strong></p><p dir="RTL"><strong>قبل إعطائك الريكسيفيو</strong>، سيفحص طبيبك تعداد دمك بحثًا عن علامات الإصابة بالعدوى. وإذا تبين أنك مصاب بأي عدوى، فسيتم علاجها قبل أن تبدأ استخدام الريكسيفيو. سيتحقق طبيبكِ أيضًا مما إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية.</p><p>&nbsp;</p><p dir="RTL"><strong>أثناء العلاج بالريكسيفيو</strong>، سيراقبك طبيبك تحسبًا لظهور علامات وأعراض الآثار الجانبية الخطيرة قبل بدء العلاج بالريكسيفيو وأثناء تلقيه، وقد يوقف العلاج بالريكسيفيو مؤقتًا أو نهائيًا إذا أُصبت بآثار جانبية معينة. وسيفحص طبيبك تعداد دمك بانتظام لأن نتائج الاختبارات المعملية غير الطبيعية الشديدة المتعلقة بالريكسيفيو تتضمن انخفاض عدد خلايا الدم البيضاء، وخلايا الدم الحمراء، والصفيحات الدموية.</p><p>&nbsp;</p><p dir="RTL"><strong>انتبه لظهور الآثار الجانبية الخطيرة.</strong></p><p dir="RTL"><strong>أخبر طبيبك أو الممرضة على الفور إذا أصبت بأي مما يلي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة إطلاق السيتوكين (CRS)، انظر القسم ٤ للاطلاع على المزيد من المعلومات حول العلامات والأعراض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشكلات العصبية، انظر القسم ٤ للاطلاع على المزيد من المعلومات حول العلامات والأعراض.</p><p>&nbsp;</p><p dir="RTL">سيراقبك طبيبك تحسبًا لظهور علامات وأعراض متلازمة إطلاق السيتوكين والمشكلات العصبية أثناء العلاج بالريكسيفيو، بالإضافة إلى الأعراض الجانبية الأخرى، وسيعالجك إذا لزم الأمر. وقد يوقف طبيبك علاجك بالريكسيفيو مؤقتًا أو نهائيًا إذا أُصبت بمتلازمة إطلاق السيتوكين، أو مشكلات عصبية، أو أي أعراض جانبية شديدة أخرى.</p><p dir="RTL">إذا كانت لديك أي أسئلة عن الريكسيفيو، فاسأل طبيبك أو الممرضة.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">ليس معروفًا إذا ما كان الريكسيفيو آمنًا وفعالًا بالنسبة للأطفال أم لا.</p><p>&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الممرضة إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. وهذا يتضمن الأدوية التي تُصرف بوصفة طبية أو من دون وصفة طبية، والفيتامينات، والمكملات العشبية.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">يمكن أن يُلحق الريكسيفيو ضررًا بجنينكِ.</p><p>&nbsp;</p><p dir="RTL"><u>معلومات الحمل الموجهة للسيدات</u></p><p dir="RTL">أخبري طبيبكِ أو ممرضتكِ قبل إعطائكِ الريكسيفيو إذا كنتِ حاملًا، أو تعتقدين أنكِ ربما تكونين حاملًا، أو تخططين للإنجاب.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ قادرة على الإنجاب، ينبغي أن يُجري طبيبكِ اختبار حمل قبل أن تبدئي العلاج.</p><p>&nbsp;</p><p dir="RTL">إذا أصبحتِ حاملًا أثناء خضوعكِ للعلاج باستخدام هذا الدواء، فأخبري طبيبكِ أو الممرضة فورًا.</p><p>&nbsp;</p><p dir="RTL"><u>منع الحمل</u></p><p dir="RTL">إذا كان من الممكن أن تصبحي حاملًا، يجب عليكِ استخدام وسيلة فعالة لتحديد النسل (وسائل منع الحمل) أثناء العلاج ولمدة ٤ أشهر بعد آخر جرعة من الريكسيفيو.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">إذا كنتِ تُرضعين رضاعة طبيعية أو تخططين لذلك. فمن غير المعروف ما إذا كان الريكسيفيو يمر إلى لبن الثدي أم لا. لذا تجنبي الرضاعة الطبيعية أثناء العلاج بالريكسيفيو ولمدة ٤ أشهر بعد آخر جرعة من الريكسيفيو.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير الريكسيفيو على القيادة واستخدام الآلات</strong></p><p dir="RTL"><strong>امتنع</strong> عن القيادة أو تشغيل الآلات الثقيلة أو الآلات التي يُحتمل أن تكون خطيرة، أو القيام بأي أنشطة خطيرة أخرى أثناء العلاج بالريكسيفيو:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمدة ٤٨ ساعة بعد الانتهاء من تلقي كلتا جرعتي الريكسيفيو اللتان تشكلان جزءًا من &quot;جدول الزيادة التدريجية للجرعات&quot;، وبعد أول جرعة علاج كاملة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وفي أي وقت أثناء العلاج بالريكسيفيو إذا ظهرت عليك أي أعراض عصبية جديدة مثل الدوار، أو التشوش، أو الرعشة (الرعاش)، أو النعاس، أو أي أعراض أخرى تؤثر على الوعي حتى تزول الأعراض، انظر القسم ٤ لمزيد من المعلومات عن علامات المشكلات العصبية وأعراضها.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي الريكسيفيو على الصوديوم</strong></p><p dir="RTL">يحتوي الريكسيفيو على أقل من ۱ مليمول من الصوديوم (٢٣ ملجم) لكل جرعة، أي أنه يُعد &quot;خاليًا من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الكمية المُعطاة</strong></p><p dir="RTL">نظرًا إلى خطر الإصابة بمتلازمة إطلاق السيتوكين، فستتلقى الريكسيفيو حسب &quot;جدول الزيادة التدريجية للجرعات&quot; وينبغي احتجازك في المستشفى لمدة ٤٨ ساعة بعد جرعة &quot;الزيادة التدريجية&quot; الأولى ولمدة ٢٤ ساعة بعد جرعة &quot;الزيادة التدريجية&quot; الثانية من الريكسيفيو.</p><p>&nbsp;</p><p dir="RTL">في أثناء تطبيق جدول الزيادة التدريجية للجرعات:</p><ul><li dir="RTL">ستتلقى &quot;جرعة الزيادة التدريجية الأولى&quot; وقدرها ١٢ ملجم في اليوم الأول من علاجك.</li><li dir="RTL">ستتلقى بعدها &quot;جرعة الزيادة التدريجية الثانية&quot; وقدرها ٣٢ ملجم في اليوم ٤ من علاجك.</li><li dir="RTL">ستتلقى بعد ذلك &quot;جرعة العلاج الكاملة&quot; وقدرها ٧٦ ملجم في اليوم ٨ من علاجك.</li><li dir="RTL">بعد أن تتلقى أول جرعة &quot;علاج&quot; كاملة، يُعطى الريكسيفيو عادة مرة واحدة كل أسبوع حتى الأسبوع ٢٤، ما دمت تحصل على فائدة من الريكسيفيو.</li><li dir="RTL">بداية من الأسبوع ٢٥، ستُعطى جرعاتك القادمة عادة مرة واحدة كل أسبوعين، ما دمت تحصل على فائدة من الريكسيفيو.</li></ul><p>&nbsp;</p><p dir="RTL">إذا تأجل موعد تلقي جرعة الريكسيفيو لأي سبب، فقد تحتاج إلى إعادة بدء جدول الزيادة التدريجية للجرعات.</p><p>&nbsp;</p><p dir="RTL">قبل كل جرعة الريكسيفيو تتلقاها ضمن جدول الزيادة التدريجية للجرعات، ستتلقى أدوية تساعد على تقليل خطر إصابتك بمتلازمة إطلاق السيتوكين. سيحدد طبيبك ما إذا كنت بحاجة إلى تلقي أدوية تساعد على تقليل خطر الإصابة بمتلازمة إطلاق السيتوكين مع الجرعات القادمة.</p><p>&nbsp;</p><p dir="RTL"><strong>كيفية إعطاء الدواء</strong></p><p dir="RTL">سيعطيك طبيبك أو الممرضة الريكسيفيو في صورة حقن تحت جلدك (الحقن تحت الجلد)، وتُعطى عادة في منطقة البطن. ويمكن أيضًا الحقن في الفخذ أو منطقة أخرى من جسمك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى المُعطاة في أثناء العلاج بالريكسيفيو</strong></p><p dir="RTL">سيتم إعطاؤك الأدوية قبل كل جرعة من جرعاتك الثلاثة الأولى من الريكسيفيو بساعة واحدة، وهو ما يساعد على تقليل فرص الإصابة بأعراض جانبية، مثل متلازمة إطلاق السيتوكين. وقد تتضمن:</p><ul><li dir="RTL">أدوية لتقليل خطر الإصابة بالحمى (مثل باراسيتامول)</li><li dir="RTL">أدوية لتقليل خطر الإصابة بالالتهاب (مثل الستيرويدات القشرية)</li><li dir="RTL">أدوية لتقليل خطر الإصابة بتفاعلات الحساسية (مضادات الهيستامين مثل ديفينهيدرامين)</li></ul><p>&nbsp;</p><p dir="RTL">قد يتم إعطاؤك هذه الأدوية أيضًا مع الجرعات اللاحقة من الريكسيفيو بناءً على أي أعراض تصاب بها.</p><p>&nbsp;</p><p dir="RTL">قد تتلقى أيضًا أدوية إضافية بناءً على أي أعراض تصاب بها أو على تاريخك الطبي.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة الزائدة من الريكسيفيو</strong></p><p dir="RTL">سيعطيك طبيبك أو الممرضة هذا الدواء. لذا فمن غير المرجح أن تتلقى كمية أكبر مما ينبغي (جرعة مفرطة)، ولكن إذا حدث ذلك، فسيفحصك طبيبك تحسبًا لظهور أعراض جانبية عليك.</p><p>&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة الريكسيفيو</strong></p><p dir="RTL">إذا فوت أي موعد، فاتصل بطبيبك أو الممرضة في أقرب وقت ممكن لإعادة جدولة موعدك. من المهم مراقبة حالتك عن كثب تحسبًا لظهور أي أعراض جانبية في أثناء العلاج بالريكسيفيو.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، فقد يسبب هذا الدواء أعراضًا جانبية، إلا أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p dir="RTL">اطلب المساعدة الطبية على الفور إذا ظهرت عليك أي من الأعراض الجانبية الخطيرة التالية التي قد تكون شديدة وربما مميتة.</p><p>&nbsp;</p><ul><li dir="RTL"><strong>متلازمة إطلاق السيتوكين (</strong><strong>CRS</strong><strong>).</strong> إن الإصابة بمتلازمة إطلاق السيتوكين شائعة في أثناء العلاج بالريكسيفيو ويمكن أيضًا أن تكون خطيرة، أو مهددة للحياة، أو ربما تؤدي إلى الوفاة. أخبر طبيبك أو الممرضة أو اطلب المساعدة الطبية على الفور إذا ظهرت عليك أي من علامات متلازمة إطلاق السيتوكين أو أعراضها، بما في ذلك:</li></ul><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>حمى تصل إلى ٣٨ درجة مئوية أو أعلى</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>صعوبة التنفس</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>القشعريرة</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الدوار أو الدوخة</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تسارع ضربات القلب</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات إنزيمات الكبد في دمك.</p><p>&nbsp;</p><ul><li dir="RTL"><strong>المشكلات العصبية. </strong>يمكن أن يسبب الريكسيفيو مشكلات عصبية قد تكون خطيرة أو مهددة للحياة. أخبر طبيبك أو الممرضة أو اطلب المساعدة الطبية على الفور إذا ظهرت عليك<strong> </strong>أي من علامات المشكلات العصبية أو أعراضها، بما في ذلك:</li></ul><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الصداع</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>التهيج، أو صعوبة البقاء مستيقظًا، أو التشوش أو التوهان، أو رؤية أو سماع أشياء غير حقيقية (الهلاوس)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>صعوبة في التحدث، أو التفكير، أو تذكر الأشياء، أو الانتباه، أو فهم الأمور</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>مشكلات في المشي، أو ضعف العضلات، أو الرعشة (الرعاش)، أو فقدان التوازن، أو تشنج العضلات</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الخدر والتنميل (الشعور &quot;بالشكشكة والوخز&quot;)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ألم حارق أو نابض أو حاد</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>حدوث تغيرات في خط يدك</p><p>&nbsp;</p><ul><li dir="RTL"><strong>حالات العدوى. </strong>إن الإصابة بحالات عدوى الجهاز التنفسي العلوي والالتهاب الرئوي شائعة في أثناء العلاج بالريكسيفيو. وقد يسبب الريكسيفيو عدوى بكتيرية وفيروسية شديدة، أو مهددة للحياة، أو قد تؤدي إلى الوفاة.</li></ul><p dir="RTL">قد يصف لك طبيبك أدوية لتساعد على منع الإصابة بالعدوى، وسيعالجك حسب الحاجة إذا أُصبت بعدوى في أثناء العلاج بالريكسيفيو.</p><p dir="RTL">أخبر طبيبك أو الممرضة على الفور إذا ظهرت عليك أي علامات أو أعراض للعدوى في أثناء تلقي العلاج بالريكسيفيو، بما في ذلك:</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>حمى تصل إلى ٣٨ درجة مئوية أو أعلى</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>القشعريرة</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>السعال</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ضيق التنفس</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ألم الصدر</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>التهاب الحلق</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ألم عند التبول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف أو التوعك بشكل عام</p><p>&nbsp;</p><ul><li dir="RTL"><strong>انخفاض تعداد خلايا الدم البيضاء. </strong>يُعد انخفاض تعداد خلايا الدم البيضاء أمرًا شائعًا في أثناء العلاج بالريكسيفيو، ويمكن أيضًا أن يكون شديدًا. وعند انخفاض تعداد خلايا الدم البيضاء يمكن أن تصاب بالحمى، وقد تكون هذه علامة على العدوى. سيعالجك طبيبك حسب الحاجة.</li></ul><p><strong>&nbsp;</strong></p><ul><li dir="RTL"><strong>مشكلات الكبد. </strong>يمكن أن يسبب الريكسيفيو زيادة إنزيمات الكبد والبيليروبين في دمك. وقد تحدث هذه الزيادات أيضًا سواءً كنت مصابًا بمتلازمة إطلاق السيتوكين أم لا.<strong> </strong>أخبر طبيبك أو ممرضتك إذا ظهرت عليك أي من علامات وأعراض مشكلات الكبد التالية:</li></ul><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>التعب</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>فقدان الشهية</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ألم في الجزء العلوي الأيمن من المعدة (البطن)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>البول داكن اللون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار جلدك أو الأجزاء البيضاء من عينيك</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> <strong>(قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل مناعي خطير يسمى &quot;متلازمة إطلاق السيتوكين&quot;</p><ul><li dir="RTL">انخفاض مستويات أحد أنواع خلايا الدم البيضاء (قلة العدلات)</li><li dir="RTL">انخفاض مستويات الأجسام المضادة المسماة &quot;الغلوبولينات المناعية&quot; في الدم (نقص غاما غلوبولين الدم)، مما يزيد احتمال الإصابة بالعدوى</li><li dir="RTL">العدوى</li></ul><p>&nbsp;</p><p dir="RTL"><strong>شائعة</strong> <strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص):</strong></p><ul><li dir="RTL">تفاعل مناعي خطير يسمى &quot;متلازمة السمية العصبية المرتبطة بالخلايا المناعية الفعالة&quot; (ICANS) من شأنه التأثير على جهازك العصبي.</li></ul><p>&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت أيًا من الأعراض الجانبية الخطيرة المذكورة أعلاه.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong></p><p dir="RTL">الأعراض الجانبية الأخرى مدرجة أدناه. أخبر طبيبك أو الممرضة إذا أصبت بأي من هذه الأعراض الجانبية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا</strong> <strong>(قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الأنف، أو الجيوب الأنفية، أو الحلق (عدوى الجهاز التنفسي العلوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات الجلدية في موضع الحقن أو بالقرب منه، بما في ذلك احمرار الجلد، أو الحكة، أو التورم، أو الألم، أو التكدم، أو الطفح الجلدي، أو النزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالرئة (التهاب رئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصفيحات الدموية (الخلايا التي تساعد على تجلط الدم؛ قلة الصفيحات في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات أحد أنواع خلايا الدم البيضاء (قلة الليمفاويات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الجلد أو الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات والعظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات &quot;البوتاسيوم&quot; في الدم (نقص بوتاسيوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور برغبة في التقيؤ (الغثيان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى شديدة في جميع أنحاء الجسم (الإنتان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا الدم البيضاء (قلة الكريات البيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيمات الكبد في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأعصاب الذي قد يسبب الوخز، أو الخدر، أو الألم، أو انعدام إحساس بالألم (اعتلال الأعصاب الطرفية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في المثانة (عدوى المسالك البولية)</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة</strong> <strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى &quot;الفوسفات&quot; في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد أحد أنواع خلايا الدم البيضاء مع وجود حمى (قلة العدلات الحموية)</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الممرضة. ويتضمن ذلك أي أعراض جانبية محتملة غير مذكورة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p>&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>مركز الاتصال الموحد: ۱۹۹۹۹</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيخزن طبيبك الريكسيفيو في المستشفى أو العيادة.</p><p>&nbsp;</p><p dir="RTL">يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">مدة الصلاحية: ۲٤ شهرا<strong>.</strong></p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المكتوب على العبوة الكرتونية، وعلى ملصق القارورة بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">يخزن في الثلاجة (من درجتين مئويتين إلى ۸ درجات مئوية). لا تقم بتجميد الدواء أو رج القارورة أو العبوة الكرتونية.</p><p>&nbsp;</p><p dir="RTL">يخزن في عبوته الكرتونية الأصلية لحمايته من الضوء.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت تغيرًا في لونه أو أي علامات تلف ظاهرة أخرى.</p><p>&nbsp;</p><p dir="RTL">ينبغي عدم التخلص من الأدوية عبر مياه الصرف أو مع النفايات المنزلية. سيتخلص طبيبك أو الممرضة من أي أدوية لم تعد مستخدمة. ستساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إلراناتاماب. يتوفر الريكسيفيو بحجمين مختلفين للعبوة:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قارورة واحدة سعة ١٫١ مل تحتوي على ٤٤ ملجم من إلراناتاماب (٤٠ ملجم/مل).</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قارورة واحدة سعة ١٫٩ مل تحتوي على ٧٦ ملجم من إلراناتاماب (٤٠ ملجم/مل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي إيديتات ثنائي الصوديوم، هيستيدين، هيدروكلوريد ل-هيستيدين أحادي الهيدرات، بولي سوربات ٨٠، سكروز، ماء للحقن (انظر &quot;يحتوي الريكسيفيو على الصوديوم&quot; في القسم ٢).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الريكسيفيو هو محلول مخصص للحقن وهو سائل عديم اللون إلى بني فاتح.</p><p dir="RTL">يأتي الريكسيفيو في عبوة كرتونية تحتوي على قارورة زجاجية واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Pfizer Inc.،</p><p dir="RTL">66 Hudson Boulevard East،</p><p dir="RTL">New York، NY 10001،</p><p dir="RTL">United States الولايات المتحدة الأمريكية</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">Pharmacia &amp; Upjohn Company<br />7000 Portage Road Kalamazoo، Michigan (MI) 49001، USA، الولايات المتحدة الأمريكية<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس/آب ۲٠۲۳.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ELREXFIO 40 mg/mL solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ELREXFIO 40 mg/mL solution for injection
One vial contains 44 mg of elranatamab in 1.1 mL (40 mg/mL).
One vial contains 76 mg of elranatamab in 1.9 mL (40 mg/mL).

Elranatamab-bcmm is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engager. It is a bispecific, humanized immunoglobulin 2-alanine (IgG2Δa) kappa antibody derived from two monoclonal antibodies (mAbs), an anti BCMA mAb and an anti-CD3 mAb. Each of these mAbs contributes one distinct heavy (H) chain and one distinct light (L) chain to the bispecific elranatamab-bcmm. The resulting 4-chain bispecific antibody is covalently linked via five inter-chain disulfide bonds. Elranatamab-bcmm is produced using two recombinant Chinese hamster ovary (CHO) cell lines, one that contains the DNA encoding the sequence for anti-BCMA monoclonal antibody (mAb) and one that contains the sequence for anti-CD3 mAb, which are grown separately in suspension culture using chemically defined (CD), animal derived component-free (ACF) media. The molecular weight of elranatamab-bcmm is approximately 148.5 kDa. The pH is 5.8.

For the full list of excipients, [see section 6.1].

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

ELREXFIO (elranatamab-bcmm) injection is a sterile, preservative-free, clear to slightly opalescent, and colorless to pale brown liquid solution for subcutaneous administration.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.</p><p>&nbsp;</p><p>This indication is approved under accelerated approval based on response rate and durability of response <em>[see section 5.1]</em>. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Important Dosing Information</em></p><p>&nbsp;</p><p>Administer ELREXFIO subcutaneously according to the step-up dosing schedule to reduce the incidence and severity of cytokine release syndrome (CRS).</p><p>&nbsp;</p><p>Administer pre-treatment medications prior to each dose in the ELREXFIO step-up dosing schedule, which includes step‑up dose 1, step-up dose 2, and the first treatment dose as recommended<em> [see </em><em>section 4.2]</em>.</p><p>&nbsp;</p><p>ELREXFIO should only be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions such as CRS and neurologic toxicity, including ICANS <em>[see </em><em>section 4.4]</em>.</p><p>&nbsp;</p><p>Due to the risk of CRS, patients should be hospitalized for 48 hours after administration of the first step-up dose, and for 24&nbsp;hours after administration of the second step-up dose.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>&nbsp;</p><p><em>Recommended</em><em> </em><em>Dosage</em></p><p>&nbsp;</p><p>For subcutaneous injection only.</p><p>&nbsp;</p><p>The recommended dosing schedule for ELREXFIO is provided in Table 1. The recommended dosages of ELREXFIO subcutaneous injection are: step-up dose 1 of 12&nbsp;mg on Day 1, step-up dose 2 of 32&nbsp;mg on Day 4, followed by the first treatment dose of 76&nbsp;mg on Day 8, and then 76 mg weekly thereafter through week 24.</p><p>&nbsp;</p><p>For patients who have received at least 24 weeks of treatment with ELREXFIO and have achieved a response [partial response (PR) or better] and maintained this response for at least 2 months, the dose interval should transition to an every two-week schedule.</p><p>&nbsp;</p><p>Continue treatment with ELREXFIO until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Administer pre-treatment medications prior to each dose in the ELREXFIO step-up dosing schedule, which includes step‑up dose 1, step-up dose 2, and the first treatment dose as recommended <em>[see&nbsp;section 4.2]</em>.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4"><p><strong>Table 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ELREXFIO Dosing Schedule</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Dosing Schedule</strong></p></td><td style="vertical-align:top"><p><strong>Day</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ELREXFIO Dose</strong></p></td></tr><tr><td rowspan="3"><p>Step-up Dosing Schedule</p></td><td style="vertical-align:top"><p>Day 1<sup>a</sup></p></td><td style="vertical-align:top"><p>Step-up dose 1</p></td><td style="vertical-align:top"><p>12&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Day&nbsp;4<sup>a,b</sup></p></td><td style="vertical-align:top"><p>Step-up dose 2</p></td><td style="vertical-align:top"><p>32&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 8<sup>a,c</sup></p></td><td style="vertical-align:top"><p>First treatment dose</p></td><td style="vertical-align:top"><p>76 mg</p></td></tr><tr><td><p>Weekly Dosing Schedule</p></td><td><p>One week after first treatment dose and weekly thereafter<sup>d </sup>through week 24</p></td><td><p>Subsequent treatment doses</p></td><td><p>76&nbsp;mg</p></td></tr><tr><td><p>Biweekly (Every 2&nbsp;Weeks) Dosing Schedule</p><p><strong>*Responders only week&nbsp;25 onward</strong></p></td><td><p>Week 25 and every 2 weeks thereafter<sup>d</sup></p></td><td><p>Subsequent treatment doses</p></td><td><p>76&nbsp;mg</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp; Administer pre-treatment medications prior to each dose in the ELREXFIO step-up dosing schedule, which includes step-up dose 1, step‑up dose 2, and the first treatment dose <em>[see section 4.2]</em>.</p></td></tr><tr><td colspan="4"><p>b.&nbsp;&nbsp;&nbsp; A minimum of 2 days should be maintained between step-up dose 1 (12&nbsp;mg) and step-up dose 2 (32&nbsp;mg).</p></td></tr><tr><td colspan="4"><p>c.&nbsp;&nbsp;&nbsp; A minimum of 3 days should be maintained between step-up dose 2 (32&nbsp;mg) and the first treatment (76&nbsp;mg) dose.</p></td></tr><tr><td colspan="4"><p>d.&nbsp;&nbsp;&nbsp; A minimum of 6 days should be maintained between treatment doses.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Note: See Table 2 for recommendations on restarting ELREXFIO after dose delays.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Recommended Pre-treatment Medications</em></p><p>&nbsp;</p><p>Administer the following pre-treatment medications approximately 1 hour before the first three doses of ELREXFIO in the step-up dosing schedule, which includes step-up dose 1, step-up dose 2, and the first treatment dose as described in Table 1 to reduce the risk of CRS <em>[see section 4.4]</em>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acetaminophen (or equivalent) 650&nbsp;mg orally</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dexamethasone (or equivalent) 20&nbsp;mg orally or intravenously</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diphenhydramine (or equivalent) 25&nbsp;mg orally</p><p>&nbsp;</p><p><em>Restarting ELREXFIO After Dosage Delay</em></p><p>&nbsp;</p><p>If a dose of ELREXFIO is delayed, restart therapy based on the recommendations listed in Table 2 and resume the dosing schedule accordingly <em>[see section 4.2]</em>. Administer pre-treatment medications as indicated in Table&nbsp;2.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><thead><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 2.</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Recommendation for Restarting Therapy with ELREXFIO After Dosage Delay</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Last Dose Administered </strong></p></td><td style="vertical-align:top"><p><strong>Time Since the Last Dose Administered </strong></p></td><td style="vertical-align:top"><p><strong>Action for Next Dose </strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Step-up dose 1 (12&nbsp;mg)</p></td><td style="vertical-align:top"><p>2 weeks or less (&le;14 days)</p></td><td style="vertical-align:top"><p>Restart ELREXFIO at step-up dose 2 (32&nbsp;mg).<sup>a</sup> If tolerated, increase to 76&nbsp;mg 4&nbsp;days later.</p></td></tr><tr><td style="vertical-align:top"><p>Greater than 2 weeks (&gt;14 days)</p></td><td style="vertical-align:top"><p>Restart ELREXFIO step-up dosing schedule at step-up dose 1 (12&nbsp;mg).<sup>a</sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Step-up dose 2 (32&nbsp;mg)</p></td><td style="vertical-align:top"><p>2 weeks or less (&le;14 days)</p></td><td style="vertical-align:top"><p>Restart ELREXFIO at 76&nbsp;mg.<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Greater than 2 weeks to less than or equal to 4 weeks (15 days to &le;28&nbsp;days)</p></td><td style="vertical-align:top"><p>Restart ELREXFIO at step-up dose 2 (32&nbsp;mg).<sup>a</sup> If tolerated, increase to 76&nbsp;mg 1 week later.</p></td></tr><tr><td style="vertical-align:top"><p>Greater than 4 weeks (&gt;28&nbsp;days)</p></td><td style="vertical-align:top"><p>Restart ELREXFIO step-up dosing schedule at step-up dose 1 (12&nbsp;mg).<sup>a</sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Any treatment dose (76&nbsp;mg)</p></td><td style="vertical-align:top"><p>6 weeks or less (&le;42 days)</p></td><td style="vertical-align:top"><p>Restart ELREXFIO at 76&nbsp;mg.</p></td></tr><tr><td style="vertical-align:top"><p>Greater than 6 weeks to less or equal to 12 weeks (43 days to &le;84 days)<sup>b</sup></p></td><td style="vertical-align:top"><p>Restart ELREXFIO at step-up dose 2 (32&nbsp;mg).<sup>a </sup>If tolerated, increase to 76 mg 1 week later.</p></td></tr><tr><td style="vertical-align:top"><p>Greater than 12 weeks (&gt;84 days)<sup>b</sup></p></td><td style="vertical-align:top"><p>Restart ELREXFIO step-up dosing schedule at step-up dose 1 (12&nbsp;mg).<sup>a</sup></p></td></tr></thead></table><p>a.&nbsp;&nbsp;&nbsp; Administer pre-treatment medications prior to the ELREXFIO dose <em>[see section 4.2]</em>.</p><p>b.&nbsp;&nbsp;&nbsp; Consider benefit-risk of restarting ELREXFIO in patients who require a dose delay of more than 42 days due to an adverse reaction.</p><p>&nbsp;</p><p><em>Dosage Modifications for Adverse Reactions</em></p><p>&nbsp;</p><p>Dosage reductions of ELREXFIO are not recommended.</p><p>&nbsp;</p><p>Dosage delays may be required to manage toxicities related to ELREXFIO <em>[see section 4.4]</em>. Recommendations on restarting ELREXFIO after a dose delay are provided in Table 2.</p><p>&nbsp;</p><p>See Table 3 and Table 4 for recommended actions for adverse reactions of CRS and ICANS, respectively. See Table 5 for recommended actions for neurologic toxicity excluding ICANS and Table 6 for recommended actions for other adverse reactions following administration of ELREXFIO. Consider further management per current practice guidelines.</p><p>&nbsp;</p><p><u>Management of CRS, Neurologic Toxicity Including ICANS</u></p><p><em>Cytokine Release Syndrome (CRS)</em></p><p>Management recommendations for CRS are summarized in Table 3.</p><p>&nbsp;</p><p>Identify CRS based on clinical presentation <em>[see section 4.4]</em>.<em> </em>Evaluate and treat other causes of fever, hypoxia, and hypotension.</p><p>&nbsp;</p><p>If CRS is suspected, withhold ELREXFIO until CRS resolves. Manage CRS according to the recommendations in Table 3 and consider further management per current practice guidelines. Administer supportive therapy for CRS, which may include intensive care for severe or life-threatening CRS. Consider laboratory testing to monitor for disseminated intravascular coagulation (DIC), hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommendations for Management of CRS</p></td></tr><tr><td style="vertical-align:top"><p>Grade<sup>a</sup></p></td><td style="vertical-align:top"><p>Presenting Symptoms</p></td><td style="vertical-align:top"><p>Actions</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Grade 1</p></td><td style="vertical-align:top"><p>Temperature &ge;100.4 &deg;F (38 &deg;C)<sup>b</sup></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until CRS resolves.<sup>c</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer pretreatment medications prior to next dose of ELREXFIO.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 2</p></td><td style="vertical-align:top"><p>Temperature &ge;100.4 &deg;F (38 &deg;C) with either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension responsive to fluid and not requiring vasopressors, and/or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of low-flow nasal cannula<sup>d</sup> or blow-by</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until CRS resolves.<sup>c</sup></p><p><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>Monitor patients daily for 48 hours following the next dose of ELREXFIO. Instruct patients to remain within proximity of a healthcare facility, and consider hospitalization.</p><p><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>Administer pretreatment medications prior to next dose of ELREXFIO.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3</p><p>(First occurrence)</p></td><td style="vertical-align:top"><p>Temperature &ge;100.4 &deg;F (38 &deg;C) with either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension requiring one vasopressor with or without vasopressin, and/or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of high-flow nasal cannula<sup>d</sup>, facemask, non‑rebreather mask, or Venturi mask</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until CRS resolves.<sup>c</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provide supportive therapy, which may include intensive care.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients should be hospitalized for 48 hours following the next dose of ELREXFIO.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer pretreatment medications prior to next dose of ELREXFIO.</p><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p>Grade 3 (Recurrent)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Temperature &ge;100.4 &deg;F (38 &deg;C) with either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension requiring one vasopressor with or without vasopressin, and/or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of high-flow nasal cannula<sup>d</sup>, facemask, non‑rebreather mask, or Venturi mask</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue therapy with ELREXFIO.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provide supportive therapy, which may include intensive care.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>Temperature &ge;100.4 &deg;F (38 &deg;C) with either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension requiring multiple vasopressors (excluding vasopressin), and/or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of positive pressure (e.g., continuous positive airway pressure [CPAP], bilevel positive airway pressure [BiPAP], intubation, and mechanical ventilation)</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue therapy with ELREXFIO.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provide supportive therapy, which may include intensive care.</p><p><s>&nbsp;</s></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp; Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading criteria for CRS.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>b.&nbsp;&nbsp;&nbsp; Attributed to CRS. Fever may not always be present concurrently with hypotension or hypoxia as it may be masked by interventions such as antipyretics or anti-cytokine therapy.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>c.&nbsp;&nbsp;&nbsp; See Table 2 for recommendations on restarting ELREXFIO after dose delays.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>d.&nbsp;&nbsp;&nbsp; Low-flow nasal cannula is &le;6 L/min, and high-flow nasal cannula is &gt;6 L/min.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Neurologic Toxicity Including ICANS</u></p><p>Management recommendations<strong> </strong>for ICANS and neurologic toxicity are summarized in Table 4 and Table 5.</p><p>&nbsp;</p><p>At the first sign of neurologic toxicity, including ICANS, withhold ELREXFIO and consider neurology evaluation. Rule out other causes of neurologic symptoms. Provide supportive therapy, which may include intensive care, for severe or life‑threatening neurologic toxicities, including ICANS <em>[see section 4.4]</em>. Manage ICANS according to the recommendations in Table 4 and consider further management per current practice guidelines.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table 4.&nbsp;&nbsp;&nbsp; Recommendations for Management of ICANS</p></td></tr><tr><td style="vertical-align:top"><p>Grade<sup>a</sup></p></td><td style="vertical-align:top"><p>Presenting Symptoms<sup>b</sup></p></td><td style="vertical-align:top"><p>Actions</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Grade 1</p></td><td style="vertical-align:top"><p>ICE score 7-9<sup>c</sup></p><p>&nbsp;</p><p>Or depressed level of consciousness<sup>d</sup>: awakens spontaneously.</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until ICANS resolves.<sup>e</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monitor neurologic symptoms and consider consultation with a neurologist and other specialists for further evaluation and management.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider non-sedating, anti-seizure medications (e.g., levetiracetam) for seizure prophylaxis.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 2</p></td><td style="vertical-align:top"><p>ICE score 3-6<sup>c</sup></p><p>&nbsp;</p><p>Or depressed level of consciousness<sup>d</sup>: awakens to voice.</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until ICANS resolves.<sup>e</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer dexamethasone<sup>f</sup> 10&nbsp;mg intravenously every 6&nbsp;hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monitor neurologic symptoms and consider consultation with a neurologist and other specialists for further evaluation and management.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider non-sedating, anti-seizure medications (e.g., levetiracetam) for seizure prophylaxis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monitor patients daily for 48 hours following the next dose of ELREXFIO. Instruct patients to remain within proximity of a healthcare facility, and consider hospitalization.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3</p><p>(First occurrence)</p></td><td style="vertical-align:top"><p>ICE score 0-2<sup>c</sup></p><p>&nbsp;</p><p>or depressed level of consciousness<sup>d</sup>: awakens only to tactile stimulus,</p><p>&nbsp;</p><p>or seizures<sup>d</sup>, either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any clinical seizure, focal or generalized, that resolves rapidly, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-convulsive seizures on electroencephalogram (EEG) that resolve with intervention,</p><p>&nbsp;</p><p>or raised intracranial pressure: focal/local edema on neuroimaging<sup>d</sup></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until ICANS resolves.<sup>e</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer dexamethasone<sup>f</sup> 10&nbsp;mg intravenously every 6&nbsp;hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monitor neurologic symptoms and consider consultation with a neurologist and other specialists for further evaluation and management.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider non-sedating, anti-seizure medications (e.g., levetiracetam) for seizure prophylaxis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provide supportive therapy, which may include intensive care.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients<strong> </strong>should be hospitalized for 48 hours following the next dose of ELREXFIO.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3 (recurrent)</p></td><td style="vertical-align:top"><p>ICE score 0-2<sup>c</sup></p><p>&nbsp;</p><p>or depressed level of consciousness<sup>d</sup>: awakens only to tactile stimulus,</p><p>&nbsp;</p><p>or seizures<sup>d</sup>, either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any clinical seizure, focal or generalized, that resolves rapidly, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-convulsive seizures on electroencephalogram (EEG) that resolve with intervention,</p><p>&nbsp;</p><p>or raised intracranial pressure: focal/local edema on neuroimaging<sup>d</sup></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue ELREXFIO.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer dexamethasone<sup>f</sup> 10&nbsp;mg intravenously every 6&nbsp;hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monitor neurologic symptoms and consider consultation with a neurologist and other specialists for further evaluation and management.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider non-sedating, anti-seizure medications (e.g., levetiracetam) for seizure prophylaxis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provide supportive therapy, which may include intensive care.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>ICE score 0<sup>c</sup></p><p><sup>&nbsp;</sup></p><p>Or, depressed level of consciousness<sup>d</sup> either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stupor or coma,</p><p>&nbsp;</p><p>or seizures<sup>d</sup>, either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life-threatening prolonged seizure (&gt;5 minutes), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; repetitive clinical or electrical seizures without return to baseline in between,</p><p>&nbsp;</p><p>or motor findings<sup>d</sup>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deep focal motor weakness such as hemiparesis or paraparesis,</p><p>&nbsp;</p><p>or raised intracranial pressure/cerebral edema<sup>d</sup>, with signs/symptoms such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diffuse cerebral edema on neuroimaging, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decerebrate or decorticate posturing, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cranial nerve VI palsy, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; papilledema, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cushing&rsquo;s triad</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue ELREXFIO.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer dexamethasone<sup>f</sup> 10&nbsp;mg intravenously every 6&nbsp;hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alternatively, consider administration of methylprednisolone 1,000&nbsp;mg per day intravenously for 3&nbsp;days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monitor neurologic symptoms and consider consultation with a neurologist and other specialists for further evaluation and management.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider non-sedating, anti-seizure medications (e.g., levetiracetam) for seizure prophylaxis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provide supportive therapy, which may include intensive care.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp; Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading criteria for ICANS.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>b.&nbsp;&nbsp;&nbsp; Management is determined by the most severe event, not attributable to any other cause.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>c.&nbsp;&nbsp;&nbsp; If patient is arousable and able to perform Immune Effector Cell-Associated Encephalopathy (ICE) Assessment, assess: Orientation (oriented to year, month, city, hospital = 4 points); Naming (name 3 objects, e.g., point to clock, pen, button = 3 points); Following Commands (e.g., &ldquo;show me 2 fingers&rdquo; or &ldquo;close your eyes and stick out your tongue&rdquo; = 1 point); Writing (ability to write a standard sentence = 1 point); and Attention (count backwards from 100 by ten = 1 point). If patient is unarousable and unable to perform ICE Assessment (Grade 4 ICANS) = 0 points.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>d.&nbsp;&nbsp;&nbsp; Not attributable to any other cause.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>e.&nbsp;&nbsp;&nbsp; See Table 2 for recommendations on restarting ELREXFIO after dose delays.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>f.<strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong>All references to dexamethasone administration are dexamethasone or equivalent medications.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 5.</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Recommendations for Management of Neurologic Toxicity, Excluding ICANS</strong></p></td></tr></tbody><thead><tr><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>Severity</strong></p></td><td style="vertical-align:top"><p><strong>Actions</strong></p></td></tr></thead><tbody><tr><td rowspan="3" style="vertical-align:top"><p>Neurologic Toxicity (excluding ICANS)</p></td><td style="vertical-align:top"><p>Grade 1</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until neurologic toxicity symptoms resolve or stabilize.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 2</p><p>Grade 3 (First occurrence)</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until neurologic toxicity symptoms improve to Grade 1 or less.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provide supportive therapy.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3 (Recurrent)</p><p>Grade 4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue ELREXFIO.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provide supportive therapy, which may include intensive care.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended Dosage Modifications for Other Adverse Reactions</p></td></tr><tr><td style="vertical-align:top"><p>Adverse Reactions</p></td><td style="vertical-align:top"><p>Severity</p></td><td style="vertical-align:top"><p>Actions</p></td></tr></thead><tbody><tr><td rowspan="4" style="vertical-align:top"><p>Hematologic Adverse Reactions</p><p><em>[see section 4.4]</em></p></td><td style="vertical-align:top"><p>Absolute neutrophil count less than 0.5 x 10<sup>9</sup>/L</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until absolute neutrophil count is 0.5 x 10<sup>9</sup>/L or higher.<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until absolute neutrophil count is 1 x 10<sup>9</sup>/L or higher and fever resolves.<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin less than 8&nbsp;g/dL</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until hemoglobin is 8&nbsp;g/dL or higher.<sup>b </sup>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count less than 25,000/mcL</p><p>&nbsp;</p><p>Platelet count between 25,000/mcL and 50,000/mcL with bleeding</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until platelet count is 25,000/mcL or higher and no evidence of bleeding.<sup>b</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Infections and Other Non‑hematologic Adverse Reactions<sup>a</sup><sup> </sup></p><p><em>[see sections 4.4 and 4.8]</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Grade 3</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ELREXFIO until adverse reaction improves to &le;Grade&nbsp;1 or baseline.<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider permanent discontinuation of ELREXFIO.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If ELREXFIO is not permanently discontinued, withhold subsequent treatment doses of ELREXFIO (e.g., doses administered after ELREXFIO step-up dosing schedule) until adverse reaction improves to Grade 1 or less.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp; Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 5.0.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>b.&nbsp;&nbsp;&nbsp; See Table 2 for recommendations on restarting ELREXFIO after dose delays.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em>Elderly </em></p><p>Of the 183 patients with relapsed or refractory multiple myeloma treated with ELREXFIO in MagnetisMM-3 at the recommended dosage, 62% were 65 years of age or older, and 19% were 75 years of age or older. No overall differences in safety or effectiveness were observed in patients 65-74 years of age compared to younger patients. Clinical studies did not include sufficient numbers of patients 75&nbsp;years of age or older to determine whether they respond differently from younger patients.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No clinically significant differences in the pharmacokinetics of elranatamab-bcmm were observed based on mild or moderate renal impairment (estimated glomerular filtration rate [eGFR] by Modification of Diet in Renal Disease [MDRD] method: 30&nbsp;to 89&nbsp;mL/min) <em>[see section 5.2]</em>.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No clinically significant differences in the pharmacokinetics of elranatamab-bcmm were observed based on mild hepatic impairment (total bilirubin 1 to &le;1.5 x ULN or any AST greater than ULN) <em>[see section 5.2]</em>.</p><p><u>&nbsp;</u></p><p><em>Paediatric population </em></p><p>The safety and effectiveness of ELREXFIO in pediatric patients have not been established.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>ELREXFIO is intended for subcutaneous use by a healthcare provider only.</p><p>&nbsp;</p><p>ELREXFIO should be administered by a healthcare provider with adequate medical personnel and appropriate medical equipment to manage severe reactions, including CRS and neurologic toxicity, including ICANS <em>[see section 4.4]</em>.</p><p>&nbsp;</p><p>For instructions on handling of the medicinal product before administration, <em>[see section 6.6]</em>.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cytokine release syndrome (CRS)</u></p><p>&nbsp;</p><p>ELREXFIO can cause CRS, including life-threatening or fatal reactions <em>[see </em><em>section 4.8</em><em>]</em>.</p><p>&nbsp;</p><p>In the clinical trial, CRS occurred in 58% of patients who received ELREXFIO at the recommended dosing schedule <em>[see&nbsp;</em><em>section 4</em><em>.2]</em>, with Grade 1 CRS in 44% of patients, Grade 2 CRS in 14% of patients, and Grade&nbsp;3 CRS in 0.5% of patients. Recurrent CRS occurred in 13% of patients. Most patients experienced CRS after the first step-up dose (43%) or the second step-up dose (19%), with 7% of patients having CRS after the first treatment dose and 1.6% of patients after a subsequent dose. The median time to onset of CRS was 2 (range: 1 to 9) days after the most recent dose, with a median duration of 2 (range: 1 to 19) days.</p><p>&nbsp;</p><p>Clinical signs and symptoms of CRS may include, but are not limited to, fever, hypoxia, chills, hypotension, tachycardia, headache, and elevated liver enzymes.</p><p>&nbsp;</p><p>Initiate therapy according to the ELREXFIO step-up dosing schedule to reduce risk of CRS and monitor patients following administration of ELREXFIO accordingly <em>[see </em><em>section 4.2</em><em>]</em>. Administer pre-treatment medications prior to each dose in the step-up dosing schedule to reduce risk of CRS <em>[see </em><em>section 4.2</em><em>]</em>.</p><p><strong>&nbsp;</strong></p><p>Counsel patients to seek medical attention should signs or symptoms of CRS occur. At the first sign of CRS, evaluate patients immediately for hospitalization. Manage CRS according to the recommendations and consider further management per current practice guidelines. Withhold or permanently discontinue ELREXFIO based on severity <em>[see&nbsp;</em><em>section 4.2</em><em>]</em>.</p><p>&nbsp;</p><p><u>Neurologic Toxicity, Including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)</u></p><p>&nbsp;</p><p>ELREXFIO can cause serious or life-threatening neurologic toxicity, including ICANS <em>[see </em><em>section 4.8</em><em>]</em>.</p><p>&nbsp;</p><p>In the clinical trial, neurologic toxicity occurred in 59% of patients who received ELREXFIO at the recommended dosing schedule <em>[see </em><em>section 4.2</em><em>]</em>, with Grade 3 or 4 neurologic toxicity occurring in 7% of patients. Neurologic toxicities included headache (18%), encephalopathy (15%), motor dysfunction (13%), sensory neuropathy&nbsp;(13%), and Guillain-Barr&eacute; Syndrome (0.5%).</p><p>&nbsp;</p><p>In the clinical trial, ICANS occurred in 3.3% of patients who received ELREXFIO at the recommended dosing schedule <em>[see </em><em>section 4.2</em><em>]</em>. Most patients had ICANS after the first step-up dose (2.7%), 1 (0.5%) patient had ICANS after the second step-up dose and 1 (0.5%) patient had ICANS after subsequent dose(s). Recurrent ICANS occurred in 1.1% of patients. The median time to onset was 3 (range: 1 to 4) days after the most recent dose, with a median duration of 2 (range: 1 to 18) days. The most frequent clinical manifestations of ICANS included a depressed level of consciousness and Grade 1 or Grade 2 Immune Effector Cell-Associated Encephalopathy (ICE) scores. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS.</p><p>&nbsp;</p><p>Counsel patients to seek medical attention should signs or symptoms of neurologic toxicity occur. Monitor patients for signs and symptoms of neurologic toxicities during treatment with ELREXFIO. At the first sign of neurologic toxicity, including ICANS, evaluate and treat patients immediately based on severity. Withhold or permanently discontinue ELREXFIO based on severity per recommendations <em>[see </em><em>section 4.2</em><em>]</em> and consider further management per current practice guidelines.</p><p>&nbsp;</p><p>Due to the potential for neurologic toxicity including ICANS, patients receiving ELREXFIO are at risk of depressed level of consciousness. Advise patients not to drive or operate heavy or potentially dangerous machinery for 48 hours after completing each of the 2 step-up doses and the first treatment dose within the ELREXFIO step-up dosing schedule and in the event of new onset of any neurological toxicity symptoms until symptoms resolve <em>[see </em><em>section 4.2</em><em>]</em>.</p><p>&nbsp;</p><p><u>Infections</u></p><p><u>&nbsp;</u></p><p>ELREXFIO can cause severe, life-threatening, or fatal infections. In the clinical trial, in patients who received ELREXFIO according to the recommended dosing schedule, serious infections, including opportunistic infections, occurred in 42% of patients, with Grade 3 or 4 infections in 31%, and fatal infections in 7%. The most common serious infections reported (&ge;5%) were pneumonia and sepsis <em>[see </em><em>section 4.8</em><em>]</em>.</p><p>&nbsp;</p><p>Do not initiate treatment with ELREXFIO in patients with active infections. Monitor patients for signs and symptoms of infection prior to and during treatment with ELREXFIO and treat appropriately. Withhold or permanently discontinue ELREXFIO based on severity <em>[see </em><em>section 4.2</em><em>]</em>. Administer prophylactic antimicrobial and anti-viral medications according to current practice guidelines. Consider treatment with subcutaneous or intravenous immunoglobulin (IVIG) as appropriate.</p><p><u>&nbsp;</u></p><p><u>Neutropenia</u></p><p>&nbsp;</p><p>ELREXFIO can cause neutropenia and febrile neutropenia. In patients who received ELREXFIO at the recommended dose in the clinical trial, decreased neutrophils occurred in 62% of patients, with Grade 3 or 4 decreased neutrophils in 51%. Febrile neutropenia occurred in 2.2% of patients <em>[see </em><em>section 4.8</em><em>]</em>.</p><p>&nbsp;</p><p>Monitor complete blood cell counts at baseline and periodically during treatment. Provide supportive care according to current practice guidelines. Monitor patients with neutropenia for signs of infection. Withhold ELREXFIO based on severity <em>[see </em><em>section 4.2</em><em>]</em>.</p><p>&nbsp;</p><p><u>Hepatotoxicity</u></p><p>&nbsp;</p><p>ELREXFIO can cause hepatotoxicity. In the clinical trial, elevated ALT occurred in 36% of patients, with Grade 3 or 4 ALT elevation occurring in 3.8%; elevated AST occurred in 40% of patients, with Grade 3 or 4 AST elevation occurring in 6%. Grade 3 or 4 total bilirubin elevations occurred in 0.5% of patients <em>[see </em><em>section 4.8</em><em>].</em> Liver enzyme elevation can occur with or without concurrent CRS.</p><p>&nbsp;</p><p>Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold ELREXFIO or consider permanent discontinuation of ELREXFIO based on severity <em>[see </em><em>section 4.2</em><em>]</em>.</p><p>&nbsp;</p><p><u>Embryo-Fetal Toxicity</u></p><p>&nbsp;</p><p>Based on its mechanism of action, ELREXFIO may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with ELREXFIO and for 4 months after the last dose <em>[see </em><em>section 4.6</em><em>]</em>.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>This medicinal product contains less than 1&nbsp;mmol (23&nbsp;mg) sodium per dose, that is to say essentially &lsquo;sodium-free.&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For certain CYP substrates, minimal changes in the concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with ELREXFIO.</p><p>&nbsp;</p><p>ELREXFIO causes release of cytokines <em>[see </em><em>section 5.1</em><em>]</em> that may suppress activity of cytochrome&nbsp;P450 (CYP) enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur after the first dose of ELREXFIO Day 1 and up to 14 days after the 32&nbsp;mg dose on Day 4 and during and after CRS <em>[see </em><em>section 4.4</em><em>].</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of child-bearing potential/Contraception </u></p><p>&nbsp;</p><p>ELREXFIO may cause fetal harm when administered to a pregnant woman.</p><p>&nbsp;</p><p><em>Pregnancy Testing</em></p><p>Verify the pregnancy status of females of reproductive potential prior to initiating treatment with ELREXFIO.</p><p>&nbsp;</p><p><em>Contraception</em></p><p>Females</p><p>Advise females of reproductive potential to use effective contraception during treatment and for 4 months after the last dose of ELREXFIO.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p><em>&nbsp;</em></p><p><em>Risk Summary</em></p><p>Based on the mechanism of action, ELREXFIO may cause fetal harm when administered to a pregnant woman <em>[see&nbsp;</em><em>section 5.1</em><em>]</em>. There are no available data on the use of ELREXFIO in pregnant women to evaluate for a drug associated risk. No animal reproductive or developmental toxicity studies have been conducted with ELREXFIO. Elranatamab-bcmm causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. In addition, based on the finding of B-cell depletion in non-pregnant animals, elranatamab-bcmm can cause B-cell lymphocytopenia in infants exposed to elranatamab-bcmm in-utero. Human immunoglobulin (IgG) is known to cross the placenta after the first trimester of pregnancy; therefore, elranatamab-bcmm has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus.</p><p>&nbsp;</p><p>ELREXFIO is associated with hypogammaglobulinemia, therefore, assessment of immunoglobulin levels in newborns of mothers treated with ELREXFIO should be considered.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><em>&nbsp;</em></p><p><em>Risk Summary</em></p><p>There are no data on the presence of elranatamab-bcmm in human milk, the effects on the breastfed child, or the effects on milk production. Maternal IgG is known to be present in human milk.</p><p>&nbsp;</p><p>Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ELREXFIO and for 4 months after the last dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No animal studies have been performed to evaluate the effects of elranatamab-bcmm on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ELREXFIO has major influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Due to the potential for ICANS, patients receiving ELREXFIO are at risk of depressed level of consciousness <em>[see section 4.8].</em> Patients should be instructed to refrain from driving or operating heavy or potential dangerous machinery during and for 48 hours after completing each of the 2 step-up doses within the ELREXFIO dosing schedule and in the event of new onset of neurologic toxicity until resolution of any neurological symptoms <em>[see sections 4.2 and 4.4].</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions are discussed elsewhere in labeling:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cytokine Release Syndrome <em>[see section 4.4]</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neurologic Toxicity, Including ICANS <em>[see section 4.4]</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections <em>[see section 4.4]</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropenia <em>[see section 4.4]</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatotoxicity <em>[see section 4.4]</em>.</p><p>&nbsp;</p><p>Clinical Trials Experience</p><p>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p><u>Relapsed/Refractory Multiple Myeloma</u></p><p><em>MagnetisMM-3</em></p><p>The safety of ELREXFIO was evaluated in MagnetisMM-3 <em>[see</em><em> section 5.1]</em>.<em> </em>The safety population described (n&nbsp;=&nbsp;183) includes patients who received the recommended dosage regimen of 12&nbsp;mg subcutaneously on Day&nbsp;1, 32&nbsp;mg on Day&nbsp;4, and 76&nbsp;mg once weekly starting on Day 8. Among patients who received ELREXFIO, 42% were exposed for 6&nbsp;months or longer and 9% were exposed for one year or longer.</p><p>&nbsp;</p><p>The median age of patients who received ELREXFIO was 68 years (range: 36 to 88 years); 48% were female; 61% were White, 10% were Hispanic/Latino, 9% were Asian, and 6% were Black or African American.</p><p>&nbsp;</p><p>Serious adverse reactions occurred in 68% of patients who received ELREXFIO at the recommended dosing schedule. Serious adverse reactions in &gt;2% of patients included pneumonia (25%), sepsis (13%), CRS (13%), upper respiratory tract infection (4.4%), acute kidney injury (3.8%), urinary tract infection (3.3%), COVID-19 (3.3%), encephalopathy (3.3%), pyrexia (2.2%), and febrile&nbsp;neutropenia&nbsp;(2.2%). Fatal adverse reactions occurred in 10% of patients including pneumonia&nbsp;(3.3%), sepsis (2.7%), acute respiratory distress syndrome (0.5%), cardio-respiratory arrest (0.5%), cardiogenic shock (0.5%), cardiopulmonary failure (0.5%), COVID-19 (0.5%), failure to thrive (0.5%), and pulmonary embolism&nbsp;(0.5%).</p><p>&nbsp;</p><p>Permanent discontinuations of ELREXFIO due to an adverse reaction occurred in 17% of patients. Adverse reactions which resulted in permanent discontinuation of ELREXFIO in &gt;2% of patients included septic shock (2.2%).</p><p>&nbsp;</p><p>Dosage interruptions of ELREXFIO due to an adverse reaction occurred in 73% of patients. Adverse reactions which resulted in dose interruptions of ELREXFIO in &gt;5% of patients included neutropenia, pneumonia, COVID-19, upper respiratory tract infection, thrombocytopenia, and anemia.</p><p>&nbsp;</p><p>The most common adverse reactions (&ge;20%) were CRS, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and pyrexia. The most common Grade&nbsp;3 to 4 laboratory abnormalities (&ge;30%) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased white blood cells, and decreased platelets.</p><p>&nbsp;</p><p>Table 7 summarizes adverse reactions in MagnetisMM-3.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3"><p><strong>Table 7.&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions (&ge;10%) in Patients with Relapsed or Refractory Multiple Myeloma Who Received ELREXFIO in MagnetisMM-3</strong></p></td></tr><tr><td><p><strong>System Organ Class</strong></p><p><strong>Preferred Term</strong></p></td><td colspan="2"><p><strong>ELREXFIO</strong></p><p><strong>N = 183</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4</strong></p><p><strong>(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cytokine release syndrome</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>0.5<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hypogammaglobulinemia<sup>*</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2.2<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and site administration conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>*</sup></p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>6<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Injection site reaction<sup>*</sup></p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>2.7<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Edema<sup>*</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>1.1<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>1.1<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>*</sup></p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>4.9</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia<sup>a</sup></p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>19</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis<sup>b</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection<sup>*</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>4.4<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>*</sup></p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>2.7<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>1.1<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>c</sup></p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Skin exfoliation<sup>*</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>*</sup></p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea<sup>*</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>3.3<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Encephalopathy<sup>d</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>2.7</p></td></tr><tr><td style="vertical-align:top"><p>Sensory neuropathy<sup>e</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0.5<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Motor dysfunction<sup>f</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2.2<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac arrhythmia<sup>*</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage<sup>*</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fall</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.5<sup>#</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Adverse reactions were graded based on CTCAE Version 5.0, with the exception of CRS, which was graded based on the ASTCT 2019 criteria.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp; Includes other related terms.</p><p>#&nbsp;&nbsp;&nbsp;&nbsp; Only grade 3 adverse reactions occurred.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia includes COVID-19 pneumonia, lower respiratory tract infection, lower respiratory tract infection viral, pneumocystis jirovecii pneumonia, pneumonia, pneumonia adenoviral, pneumonia bacterial, pneumonia cytomegaloviral, pneumonia fungal, pneumonia influenzal, pneumonia pseudomonal, pneumonia viral.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sepsis includes bacteremia, device related bacteremia, device related sepsis, escherichia bacteremia, escherichia sepsis, klebsiella sepsis, pseudomonal sepsis, sepsis, septic shock, staphylococcal bacteremia, staphylococcal sepsis, streptococcal sepsis, urosepsis.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash incudes erythema, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash pustular, symmetrical drug-related intertriginous and flexural exanthema.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Encephalopathy includes agitation, altered state of consciousness, cognitive disorder, confusional state, delirium, depressed level of consciousness, disorientation, hallucination, lethargy, memory impairment, mental status changes, metabolic encephalopathy, somnolence, toxic encephalopathy.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensory neuropathy includes burning sensation, dysesthesia, hypoesthesia, neuropathy peripheral, paresthesia, parosmia, peripheral sensorimotor neuropathy, peripheral sensory neuropathy, polyneuropathy, sensory loss.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Motor dysfunction includes ataxia, balance disorder, gait disturbance, motor dysfunction, muscle contracture, muscle spasms, muscular weakness, peripheral motor neuropathy, peroneal nerve palsy, tremor.</p></td></tr></tbody></table><p>&nbsp;</p><p>Clinically relevant adverse reactions in &lt;10% of patients who received ELREXFIO included ICANS, febrile neutropenia, Guillain-Barr&eacute; syndrome, abdominal pain, acute kidney injury, COVID-19, cardiac failure, congestion, and thrombosis.</p><p>&nbsp;</p><p>Table 8 summarizes laboratory abnormalities in MagnetisMM-3.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3"><p><strong>Table 8.</strong>&nbsp;&nbsp;&nbsp;&nbsp; <strong>Select Laboratory Abnormalities (&ge;30%) That Worsened from Baseline in Patients with Relapsed or Refractory Multiple Myeloma Who Received ELREXFIO in MagnetisMM-3<sup>a</sup></strong></p></td></tr></thead><tbody><tr><td rowspan="2"><p><strong>Laboratory Abnormality</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ELREXFIO<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Grades (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4 (%)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Hematology</strong></p></td></tr><tr><td style="vertical-align:top"><p>Lymphocyte count decreased</p></td><td style="vertical-align:top"><p>91</p></td><td style="vertical-align:top"><p>84</p></td></tr><tr><td style="vertical-align:top"><p>White blood cell decreased</p></td><td style="vertical-align:top"><p>69</p></td><td style="vertical-align:top"><p>40</p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin decreased</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>43</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophil count decreased</p></td><td style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>51</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count decreased</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Chemistry</strong></p></td></tr><tr><td style="vertical-align:top"><p>Albumin decreased</p></td><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>AST increase</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine increased</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>3.3</p></td></tr><tr><td style="vertical-align:top"><p>Potassium decreased</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>ALT increase</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>3.8</p></td></tr><tr><td style="vertical-align:top"><p>Alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine clearance decreased</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laboratory tests were graded according to NCI-CTCAE Version 5.0.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The denominator used to calculate the rate varied from 181 to 183 based on the number of patients with a baseline value and at least one post‑treatment value.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p><strong>To report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No participant reported an elranatamab overdose in the clinical trial program and the maximum tolerated dose of elranatamab has not been determined. In clinical studies, doses up to 76&nbsp;mg QW have been administered.</p><p><u>&nbsp;</u></p><p><u>Treatment</u></p><p>In the event of an overdose, the patient should be monitored for any signs or symptoms of adverse reactions and appropriate supportive treatment should be instituted immediately.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mechanism of action</u></p><p>Elranatamab-bcmm is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody that binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells leading to cytolysis of the BCMA‑expressing cells. Elranatamab-bcmm activated T-cells, caused proinflammatory cytokine release, and resulted in multiple myeloma cell lysis.</p><p>&nbsp;</p><p><u>Cytokine Concentrations</u></p><p>Transient elevation of circulating cytokines IL-2, IL-6, IL-8, IL-10, TNF-&alpha;, and IFN-&gamma; was observed at dosage levels of 30&nbsp;&micro;g/kg (0.03 times the approved recommended dosage) and above. After administration of the approved recommended dosage of ELREXFIO, the highest elevation of cytokines was generally observed within 72 hours after first elranatamab‑bcmm dose at 12&nbsp;mg on Day 1, and generally returned to baseline prior to the administration of the first full dose 76&nbsp;mg on Day 8.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of elranatamab-bcmm or of other elranatamab products.</p><p>&nbsp;</p><p>In the MagnetisMM-3 study, of the 168 participant who received recommended step-up and full dosage of ELREXFIO for up to 24 month and are evaluable for presence of ADA against elranatamab-bcmm, 8.9% (15/168) of patients tested positive for anti-elranatamab-bcmm-antibodies. Among the 15 patients who tested positive for ADAs, 60% (9/15) tested positive for neutralizing antibodies against elranatamab-bcmm. The effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of ELREXFIO products is unknown.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Relapsed</em><em> or Refractory Multiple Myeloma</em></p><p>&nbsp;</p><p>The efficacy of ELREXFIO monotherapy was evaluated in patients with relapsed or refractory multiple myeloma in an open-label, single arm, multi-center study (MagnetisMM-3, NCT04649359). The study included patients who were refractory to at least one proteasome inhibitor (PI), one immunomodulatory agent (IMiD), and one anti-CD38 monoclonal antibody. MagnetisMM-3 included 123 patients na&iuml;ve to prior BCMA-directed therapy (pivotal Cohort A) and 64&nbsp;patients with prior BCMA-directed antibody drug conjugate (ADC) or chimeric antigen receptor (CAR) T‑cell therapy (supportive Cohort B). Patients had measurable disease by International Myeloma Working Group (IMWG) criteria at enrollment. The study included patients with an Eastern Cooperative Oncology Group (ECOG) score of &le;2, adequate baseline bone marrow (absolute neutrophil count &ge;1.0 x 10<sup>9</sup>/L, platelet count &ge;25 x 10<sup>9</sup>/L, hemoglobin level &ge;8&nbsp;g/dL), renal (CrCL &ge;&nbsp;30 mL/min), and hepatic (AST and ALT &le;2.5 x ULN, total bilirubin &le;2 x ULN) function, and left‑ventricular ejection fraction &ge;40%. Patients with a stem cell transplant within 12 weeks prior to enrollment and active infections were excluded from the study.</p><p>&nbsp;</p><p>Eligible patients received subcutaneous administration of ELREXFIO at step-up doses of 12 mg on Day 1 and 32 mg on Day&nbsp;4 of treatment, followed by the first treatment dose of ELREXFIO (76 mg) on Day 8 of treatment. Thereafter, patients received 76 mg once weekly. After 24 weeks, in patients who achieved an IMWG response category of partial response or better with responses persisting for at least 2 months, the dose interval was changed from every week to every 2&nbsp;weeks.</p><p>&nbsp;</p><p>The 123 patients enrolled in pivotal Cohort A had received a median of 5 prior lines of therapy (range: 2 to 22). Ninety‑seven patients who were not exposed to prior BCMA‑directed therapy and received at least four prior lines of therapy comprised the efficacy population. Among the 97 patients in the efficacy population, the median age was 69 (range:&nbsp;46 to 89) years with 18.6% of patients &ge;75 years of age. Forty percent were female; 59.8% were White, 13.4% were Asian, 7.2% were Hispanic/Latino, 5.2% were Black or African American. Disease stage (R-ISS) at study entry was 20.6% in Stage I, 53.6% in Stage II, and 17.5% in Stage III. The median time since initial diagnosis of multiple myeloma to enrollment was 79.6 (range: 16 to 228) months. 96.9% were triple-class refractory, and 94.8% were refractory to their last line of therapy. 69.1% received prior autologous stem cell transplantation, and 7.2% received prior allogenic stem cell transplantation. High-risk cytogenetics [t(4;14), t(14;16), or del(17p)] were present in 22.7% of patients. 34.0% of patients had extramedullary disease at baseline by BICR.</p><p>&nbsp;</p><p>Efficacy was based on response rate and duration of response (DOR), as assessed by BICR based on IMWG criteria. Efficacy results from BCMA-directed therapy na&iuml;ve patients are shown in Table 9.</p><p>&nbsp;</p><p>The median (range) time to first response (TTR) was 1.22 (0.9 to 6.5) months. With a median follow-up of 11.1 months (95% CI: 10.6, 12.0) among responders, the DOR rate at 6 months was 90.4% (95% CI: 78.4%, 95.9%) and at 9 months was 82.3% (95% CI: 67.1%, 90.9%).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Table 9.&nbsp;&nbsp;&nbsp;&nbsp; Efficacy Results from BCMA-directed Therapy Na&iuml;ve Patients</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>N = 97</strong></p></td></tr><tr><td style="vertical-align:top"><p>Objective Response Rate (ORR: sCR+CR+VGPR+PR), n (%) (95% CI)</p></td><td style="vertical-align:top"><p>56 (57.7%)</p><p>(47.3, 67.7)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response (CR) or better<sup>a</sup></p></td><td style="vertical-align:top"><p>25 (25.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Very good partial response (VGPR)</p></td><td style="vertical-align:top"><p>25 (25.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Partial response (PR)</p></td><td style="vertical-align:top"><p>6 (6.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Duration of Response (DOR) (months)</p><p>Median (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NR (12.0, NE)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Abbreviations: CI = Confidence interval; NR = Not reached; NE = Not estimable.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp;&nbsp; Complete response or better = Stringent complete response (sCR) + complete response (CR).</p></td></tr></tbody></table><p>&nbsp;</p><p>Among the 64 patients enrolled in Cohort B who previously received a PI, an IMiD, an anti-CD38 monoclonal antibody, and a BCMA-directed therapy, 63 patients received at least four prior lines of therapy. Patients had received a median of 8&nbsp;prior lines of therapy (range: 4 to 19); 73% and 32% received prior BCMA-directed ADC and CAR T‑cell therapy, respectively.&nbsp;</p><p>&nbsp;</p><p>Confirmed ORR by BICR was 33.3%&nbsp;(95% CI: 22.0, 46.3). After a median (95% CI) follow-up of 10.2 (9.9, 11.0) months among responders, median DOR was not reached (95% CI: NE, NE) and the DOR rate at 9 months was 84.3% (95% CI: 58.7, 94.7).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic parameters are presented as geometric mean (coefficient of variation [CV]%) and are based upon subcutaneously administered unless otherwise specified.</p><p>&nbsp;</p><p>Elranatamab-bcmm exhibits dose proportional pharmacokinetics over dose range from 6 to 76&nbsp;mg (0.079 to 1 times the approved recommended dosage). Elranatamab-bcmm maximum concentration [33.6 mcg/mL (48%)] is achieved at the end of weekly dosing regimen (i.e., at week 24 of 76 mg weekly dosing). Pharmacokinetic exposures are summarized for the recommended dosage of ELREXFIO in Table 10.</p><p><strong>&nbsp;</strong></p><p><strong>Table 10.&nbsp;&nbsp; Pharmacokinetic Parameters of Elranatamab-bcmm in Subjects with Relapsed or Refractory Multiple Myeloma </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2"><p><strong>Timepoint</strong></p></td><td colspan="3"><p><strong>Parameters</strong></p></td></tr><tr><td><p><strong>C<sub>avg</sub></strong></p><p><strong>(mcg/mL)</strong></p></td><td><p><strong>C<sub>max</sub></strong></p><p><strong>(mcg/mL)</strong></p></td><td><p><strong>C<sub>trough</sub></strong></p><p><strong>(</strong><strong>mcg/mL)</strong></p></td></tr><tr><td><p>First full 76 mg dose</p></td><td><p>3.1 (94%)</p></td><td><p>3.8 (94%)</p></td><td><p>3.3 (102%)</p></td></tr><tr><td><p>End of weekly dose (week 24)<sup>a</sup></p></td><td><p>32.7 (49%)</p></td><td><p>33.6 (48%)</p></td><td><p>31.2 (50%)</p></td></tr><tr><td><p>Steady state (biweekly dosing)<sup>a,b</sup></p></td><td><p>18.4 (57%)</p></td><td><p>20.1 (55%)</p></td><td><p>15.9 (64%)</p></td></tr><tr><td colspan="4"><p>a.<strong>&nbsp;&nbsp;&nbsp; </strong>In patients who have achieved a response.</p></td></tr><tr><td colspan="4"><p>b.<strong>&nbsp;&nbsp;&nbsp; </strong>Steady state exposure of elranatamab biweekly dose is approximated at week 48.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Absorption</u></p><p>The mean bioavailability of elranatamab-bcmm was 56.2% when administered subcutaneously. The median (min, max) T<sub>max</sub> after elranatamab SC administration was 7 (3 to 7) days.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>The steady state volume of distribution of elranatamab-bcmm was 7.76 L (33%).</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>The half-life of elranatamab-bcmm is 22 (64%) days at the 76 mg dosage, with clearance of 0.324 L/day (100%) following 24 weeks dosing.</p><p><em><u>&nbsp;</u></em></p><p><em>Metabolism</em></p><p>Elranatamab-bcmm is expected to be metabolized into small peptides by catabolic pathways.</p><p><em>&nbsp;</em></p><p><u>Specific Populations</u></p><p>No clinically significant differences in the pharmacokinetics of elranatamab-bcmm were observed based on age (36 to 89&nbsp;years), sex, race (White, Asian, or Black), body weight (37 to 160 kg), mild or moderate renal impairment (estimated glomerular filtration rate [eGFR] by Modification of Diet in Renal Disease [MDRD] method: 30&nbsp;to 89&nbsp;mL/min), or mild hepatic impairment (total bilirubin 1 to &le;1.5 x ULN or any AST greater than ULN).</p><p>&nbsp;</p><p>The effects of severe renal impairment (eGFR 15 to 29 mL/min), end-stage renal disease (eGFR &lt;15 mL/min), or moderate to severe hepatic impairment (total bilirubin &gt;1.5 times ULN and any AST) on the PK of elranatamab-bcmm are unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No carcinogenicity or genotoxicity studies have been conducted with elranatamab-bcmm.</p><p><u>&nbsp;</u></p><p>No animal studies have been performed to evaluate the effects of elranatamab-bcmm on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>edetate disodium dihydrate (0.05&nbsp;mg)</p><p>histidine (1.12&nbsp;mg)</p><p>L-histidine hydrochloride monohydrate (2.67&nbsp;mg)</p><p>polysorbate 80 (0.2&nbsp;mg)</p><p>sucrose (85&nbsp;mg)</p><p>Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
24 months.

Prepared syringe 
Once the vial is punctured, it is intended to be administered immediately, or within 24 hours when stored between 2 to 30°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store refrigerated at 2&nbsp;&deg;C to 8&nbsp;&deg;C in the original carton until time of use to protect from light.</p><p>Do not freeze or shake the vial or carton.</p><p>&nbsp;</p><p>For storage conditions after first opening of the medicinal product, <em>[see section 6.3].</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ELREXFIO (elranatamab-bcmm) injection is a sterile, preservative-free, clear to slightly opalescent, and colorless to pale brown liquid solution supplied as follows:</p><ul><li>One 76 mg/1.9 mL (40 mg/mL) single-dose vial in a carton.</li><li>One 44 mg/1.1 mL (40 mg/mL) single-dose vial in a carton.</li></ul><p>&nbsp;</p><p>ELREXFIO is supplied in a single-dose glass vial sealed with a rubber stopper (not made of natural rubber latex) and an aluminum seal with a flip-off cap.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Preparation and Administration</em></strong><strong><em> </em></strong><strong><em>Instructions</em></strong><strong><em><u> </u></em></strong></p><p><u>&nbsp;</u></p><p>ELREXFIO 76&nbsp;mg/1.9 mL (40&nbsp;mg/mL) vial and 44&nbsp;mg/1.1 mL (40&nbsp;mg/mL) vial are supplied as ready-to-use solution that do not need dilution prior to administration.</p><p>&nbsp;</p><p>ELREXFIO is a clear to slightly opalescent, and colorless to pale brown liquid solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer if solution is discolored or contains particulate matter.</p><p>&nbsp;</p><p>Use aseptic technique to prepare and administer ELREXFIO.</p><p>&nbsp;</p><p><u>Preparation</u></p><p>ELREXFIO vials are for one-time use in a single patient and do not contain any preservatives.</p><p>&nbsp;</p><p>Prepare ELREXFIO following the instructions below (see Table 11) depending on the required dose. Use a 44&nbsp;mg/1.1&nbsp;mL (40&nbsp;mg/mL) single-dose vial for step-up dose 1 or step-up dose 2.</p><p>&nbsp;</p><p><strong>Table 11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection Volumes</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:390px"><thead><tr><td style="vertical-align:top"><p><strong>Total Dose (mg)</strong></p></td><td style="vertical-align:top"><p><strong>Volume of Injection</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>12 mg</p></td><td style="vertical-align:top"><p>0.3 mL</p></td></tr><tr><td style="vertical-align:top"><p>32 mg</p></td><td style="vertical-align:top"><p>0.8 mL</p></td></tr><tr><td style="vertical-align:top"><p>76 mg</p></td><td style="vertical-align:top"><p>1.9 mL</p></td></tr></tbody></table><p>&nbsp;</p><p>Remove the appropriate strength ELREXFIO vial from refrigerated storage [2 &deg;C to 8 &deg;C]. Once removed from refrigerated storage, equilibrate ELREXFIO to ambient temperature [15 &deg;C to 30 &deg;C]. Do not warm ELREXFIO in any other way.</p><p>&nbsp;</p><p>Withdraw the required injection volume of ELREXFIO from the vial into an appropriately sized syringe with stainless steel injection needles (30G or wider) and polypropylene or polycarbonate syringe material. Discard unused portion.</p><p>&nbsp;</p><p><u>Administration</u></p><p>Inject the required volume of ELREXFIO into the subcutaneous tissue of the abdomen (preferred injection site). Alternatively, ELREXFIO may be injected into the subcutaneous tissue at other sites (e.g., thigh).</p><p>&nbsp;</p><p>Do not inject into tattoos or scars or areas where the skin is red, bruised, tender, hard or not intact.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder 
Pfizer Inc., 
66 Hudson Boulevard East, 
New York, NY 10001,
United States

Manufacturer
Pharmacia & Upjohn Company 
7000 Portage Road Kalamazoo, Michigan (MI) 49001, USA


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>